logo-loader
RNS
viewHikma Pharmaceuticals PLC

Hikma Pharmaceutical - Result of AGM

RNS Number : 5097L
Hikma Pharmaceuticals Plc
30 April 2020
 

 

Hikma Pharmaceuticals PLC

Voting Results of 2020 Annual General Meeting

LONDON, 30 April 2020 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BB+/positive S&P) announces its Annual General Meeting ("AGM"), held at 22 Regent Road, Surbiton KT5 8NL on 30 April 2020 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 18 were passed as ordinary resolutions and Resolutions 19 to 22 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 26 February 2020) is set out below. The number of Ordinary Shares in issue on 30 April 2020 was 242,543,355.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1. To receive the 2019 report and accounts

201,698,273

99.99

57

0.01

201,698,330

1,120,694

2. To approve a final dividend of 30 cents per share

202,811,365

99.99

6,764

0.01

202,818,129

895

3. To re-appoint PricewaterhouseCoopers LLP as auditors

202,808,789

99.99

8,990

0.01

202,817,779

1,245

4.To authorise the Audit Committee to determine the auditors' remuneration

202,814,187

99.99

3,664

0.01

202,817,851

1,173

5. To elect Cynthia Schwalm as a director

201,548,814

99.37

1,268,304

0.63

202,817,118

1,906

6. To re-elect Said Darwazah as a director

196,190,726

96.77

6,538,997

3.23

202,729,723

89,301

7. To re-elect Siggi Olafsson as a director

200,700,552

98.96

2,117,034

1.04

202,817,586

1,438

8. To re-elect Mazen Darwazah as a director

197,442,264

97.35

5,375,322

2.65

202,817,586

1,438

9. To re-elect Robert Pickering as a director

196,820,454

97.04

5,996,664

2.96

202,817,118

1,906

10.To re-elect Ali Al-Husry as a director

199,416,313

98.32

3,401,273

1.68

202,817,586

1,438

11. To re-elect Patrick Butler as a director

199,744,398

98.48

3,073,188

1.52

202,817,586

1,438

12. To re-elect Dr. Pamela Kirby as a director

195,639,660

96.46

7,177,925

3.54

202,817,585

1,438

13. To re-elect Dr. Jochen Gann as a director

199,704,876

98.47

3,112,710

1.53

202,817,586

1,438

14. To re-elect John Castellani as a director

199,425,273

98.80

2,426,100

1.20

201,851,373

967,651

15. To re-elect Nina Henderson as a director

200,433,121

98.82

2,384,465

1.18

202,817,586

1,438

16. To approve the remuneration policy

190,931,576

95.50

8,992,802

4.50

199,924,378

2,894,646

17. To approve the remuneration report for the year ended 31 December 2019

190,252,825

95.16

9,671,582

4.84

199,924,407

2,894,616

18. Authority to allot shares

177,783,521

87.66

25,033,088

12.34

202,816,609

2,415

19. To dis-apply pre-emption rights for general purposes

202,778,888

99.98

37,721

0.02

202,816,609

2,415

20. To dis-apply pre-emption rights for an acquisition or other capital investment

201,813,423

99.51

1,003,156

0.49

202,816,579

2,445

21. To authorise the Company to purchase its own shares

201,634,579

99.44

1,133,921

0.56

202,768,500

50,524

22. To authorise the Company to hold general meetings on no less than 14 clear days' notice

197,970,909

97.61

4,846,842

2.39

202,817,751

1,273

 

Declaration of final dividend

The dividend of 30 cents per share will be paid on 7 May 2020 to shareholders on the register on 20 March 2020.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.238806 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

EVP, Strategic Planning and Global Affairs

 

+44 20 7399 2670

 

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSDIFSSESSEIL

Quick facts: Hikma Pharmaceuticals PLC

Price: 2100

Market: AIM
Market Cap: £4.84 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE